As of November 15, 2026, Atrium Therapeutics, Inc. is a publicly traded company (Nasdaq: RNA); its largest reported holder is Sessa Capital IM, L.P., with 8.8% on Schedule 13G of August 14, 2026, then T. Rowe Price (8.6%). The largest insider holding is Sarah Boyce, a director, with 138,668 shares (0.64% of shares outstanding), per Form 4 of September 22, 2026 (Schedule 13G, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Atrium Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Atrium Therapeutics, Inc. a real, registered company?
- Atrium Therapeutics, Inc. files with the SEC under CIK 2093101 (its SEC filings).
- Its shares are listed under the ticker RNA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ATRIUM THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-15).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names T. Rowe Price (filed 2026-08-14).
Who are Atrium Therapeutics, Inc.'s owners and officers?
Atrium Therapeutics, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | T. Rowe Price Associates, Inc. | 8.6% |
| Schedule 13G, 2026-08-14 | Sessa Capital Im, L.P. | 8.8% |
| Schedule 13G/A, 2026-08-14 | Ra Capital Management, L.P. | 0% |
| Schedule 13G/A, 2026-07-27 | Blackrock, Inc. | 6.6% |
| Schedule 13G, 2026-05-15 | Ra Capital Management, L.P. | 5.6% |
| Schedule 13G, 2026-04-27 | Blackrock, Inc. | 5.2% |
| Schedule 13G, 2026-04-08 | T. Rowe Price Associates, Inc. | 10% |
Questions about who owns Atrium Therapeutics, Inc.
Who owns Atrium Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Atrium Therapeutics, Inc.: Sessa Capital Im, L.P. (8.8%, Schedule 13G, filed 2026-08-14), T. Rowe Price Associates, Inc. (8.6%, Schedule 13G/A, filed 2026-08-14) and Blackrock, Inc. (6.6%, Schedule 13G/A, filed 2026-07-27).
Who are the largest shareholders of Atrium Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Atrium Therapeutics, Inc. on this page are Sessa Capital Im, L.P. (8.8%), T. Rowe Price Associates, Inc. (8.6%) and Blackrock, Inc. (6.6%).
When did Sessa Capital Im, L.P. buy into Atrium Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Sessa Capital Im, L.P. on this page is the Schedule 13G, filed 2026-08-14, reporting 8.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Atrium Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Atrium Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Atrium Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Atrium Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 138,668 shares (0.64% of shares outstanding) (Form 4, 2026-09-22).
- , a director: 119,729 shares (0.56% of shares outstanding) (Form 4, 2026-09-22).
- , the chief medical officer: 51,638 shares (0.24% of shares outstanding) (Form 4, 2026-09-22).
- , the chief scientific officer: 41,441 shares (0.19% of shares outstanding) (Form 4, 2026-09-22).
- , the chief strategy officer: 38,340 shares (0.18% of shares outstanding) (Form 4, 2026-09-22).
Shares outstanding: 21,571,507 as of 2026-11-02, from the company's latest SEC cover page.
How much has Atrium Therapeutics, Inc. raised?
No fundraising or offering filing from Atrium Therapeutics, Inc. is on file with us.
Keep reading
More on Atrium Therapeutics, Inc. and the records around it.
Companies that share a holder
- Sessa Capital IM, L.P. also filed stake reports on 3 other companies: Sotera Health Co (Aug 2026), TreeHouse Foods, Inc. (Jan 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Evommune, Inc. (Nov 2026), Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026)
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: PACIFIC BIOSCIENCES OF CALIF (Nov 2026), APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/atrium-therapeutics